Navigation Links
Male Contraceptive Pill Being Developed By Berlin Pharmaceutical

A Berlin-based pharmaceutical company, Schering, has obtained promising results in the development of a male contraceptive pill//.

The male contraceptive, which comes almost 45 years after Schering developed the female contraceptive pill, is just skin deep - in the form of an implanted hormonal capsule and an injection given every few months.

This project is headed by a slightly-built 53-year-old woman, Professor Ursula-Friederike Habenicht, who runs the global Gynaecology and Andrology Research sector for Schering.

"This is just an initial step, just getting a foot in the door," says Habenicht, who has long been considering possible approaches to male contraception.

Habenicht is in charge of a large group of scientists who are pursuing these ideas in teams scattered through various laboratories.

The main problem facing the researchers is the fact that a woman releases just one egg per month that might be fertilised, whereas a man produces between 70 and 100 million sperm per day - and all of these without exception have to be reined in.

"The combination of the gestagene (hormonal capsule) implant and the testosterone injection causes the brain to stop the sperm production in the testicles," the professor says.

This occurs because the procedure artificially increases the level of body's testosterone, leading the brain to believe that sufficient sperm are already present. It therefore ceases to send out signals ordering further production.

Since the complete sperm production cycle requires 70 days on the average, it takes quite a while for the very last little critter to disappear. Only after three to six months is the sperm count reduced to zero.

"This long preliminary stage cannot be altered biologically," the professor explains.

Furthermore, there is still no substitute for the bothersome injection. "If you swallow testosterone in pill form, it is broke
'"/>




Page: 1 2

Related medicine news :

1. Contraceptives via Internet
2. FDA Approves Contraceptive Ring
3. Contraceptives decreases Libido
4. Contraceptives have dual effects
5. Drugs For Anthrax May Interfere With Oral Contraceptives
6. Contraceptive pill to reduce PMS
7. Smoking and Oral Contraceptives:
8. Contraceptive pills may lead to deformities in babies
9. Low-Dose Oral Contraceptives May Increase Risk For Heart Attack Or Stroke
10. Prevent Multiple Sclerosis From Oral Contraceptives
11. Usage Of Oral Contraceptives Need Not Be Feared By SLE Patients
Post Your Comments:
Breaking Medicine News(10 mins):Health News:NeuroFocus Adds Two More of the World's Leading Neuroscientists to its Advisory Board 2Health News:NeuroFocus Adds Two More of the World's Leading Neuroscientists to its Advisory Board 3Health News:Statement of HDMA President and CEO John M. Gray on the Importation of Prescription Drugs 2Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 2Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 3Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 4Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 5Health News:Fastrack Announces Enhancements to the Enterprise System for HME/Respiratory Providers 2Health News:Fastrack Announces Enhancements to the Enterprise System for HME/Respiratory Providers 3Health News:Fastrack Announces Enhancements to the Enterprise System for HME/Respiratory Providers 4Health News:Sushi & Breastfeeding Join Birth Defects & Preterm Birth as Leading Concerns of Moms 2
Breaking Medicine Technology:Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 2Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan 3Sundia MediTech Appoints Dr Tong Xu as VP of Process Chemistry 12816 1Sundia MediTech Appoints Dr Tong Xu as VP of Process Chemistry 12816 2AcelRx Announces Positive Phase 2 Results from a Study of ARX 01 Sufentanil NanoTabs in Treating Post Operative Pain 4664 1AcelRx Announces Positive Phase 2 Results from a Study of ARX 01 Sufentanil NanoTabs in Treating Post Operative Pain 4664 2AcelRx Announces Positive Phase 2 Results from a Study of ARX 01 Sufentanil NanoTabs in Treating Post Operative Pain 4664 3AcelRx Announces Positive Phase 2 Results from a Study of ARX 01 Sufentanil NanoTabs in Treating Post Operative Pain 4664 4Tanning Chain Offers Tips for Effective Indoor and Outdoor Exposure 50246 1Tanning Chain Offers Tips for Effective Indoor and Outdoor Exposure 50246 2